Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

Prudhvi Regula; David Rosenstreich; Elina Jerschow; Manish Ramesh; Denisa Ferastraoaru; Jessica Oh; Daniella S. Aivazi; Jonathan M. Aivazi; Golda Hudes

doi:10.1016/j.jacig.2022.04.005

Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

Prudhvi Regula, David Rosenstreich, Elina Jerschow, Manish Ramesh, Denisa Ferastraoaru, Jessica Oh, Daniella S. Aivazi, Jonathan M. Aivazi, Golda Hudes

Medicine

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

Original language	English (US)
Pages (from-to)	175-177
Number of pages	3
Journal	Journal of Allergy and Clinical Immunology: Global
Volume	1
Issue number	3
DOIs	https://doi.org/10.1016/j.jacig.2022.04.005
State	Published - Aug 2022

Keywords

COVID-19 vaccines
Graded dosing of vaccine
mRNA vaccine allergy
vaccine desensitization
vaccine hesitancy

ASJC Scopus subject areas

Immunology and Allergy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jacig.2022.04.005

Cite this

Regula, P., Rosenstreich, D., Jerschow, E., Ramesh, M., Ferastraoaru, D., Oh, J., Aivazi, D. S., Aivazi, J. M., & Hudes, G. (2022). Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose. Journal of Allergy and Clinical Immunology: Global, 1(3), 175-177. https://doi.org/10.1016/j.jacig.2022.04.005

Regula, P, Rosenstreich, D, Jerschow, E, Ramesh, M , Ferastraoaru, D , Oh, J, Aivazi, DS, Aivazi, JM & Hudes, G 2022, 'Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose', Journal of Allergy and Clinical Immunology: Global, vol. 1, no. 3, pp. 175-177. https://doi.org/10.1016/j.jacig.2022.04.005

@article{52bcfd3a06b54432a7e2b8c9287b6d09,

title = "Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose",

abstract = "Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.",

keywords = "COVID-19 vaccines, Graded dosing of vaccine, mRNA vaccine allergy, vaccine desensitization, vaccine hesitancy",

author = "Prudhvi Regula and David Rosenstreich and Elina Jerschow and Manish Ramesh and Denisa Ferastraoaru and Jessica Oh and Aivazi, {Daniella S.} and Aivazi, {Jonathan M.} and Golda Hudes",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = aug,

doi = "10.1016/j.jacig.2022.04.005",

language = "English (US)",

volume = "1",

pages = "175--177",

journal = "Journal of Allergy and Clinical Immunology: Global",

issn = "2772-8293",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

AU - Regula, Prudhvi

AU - Rosenstreich, David

AU - Jerschow, Elina

AU - Ramesh, Manish

AU - Ferastraoaru, Denisa

AU - Oh, Jessica

AU - Aivazi, Daniella S.

AU - Aivazi, Jonathan M.

AU - Hudes, Golda

PY - 2022/8

Y1 - 2022/8

N2 - Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

AB - Current guidelines do not recommend subsequent mRNA COVID-19 vaccination in patients who experience immediate allergic reactions to the first dose. Our findings indicate that graded dosing of this vaccine is safe, efficacious, and useful for treating these individuals with allergy.

KW - COVID-19 vaccines

KW - Graded dosing of vaccine

KW - mRNA vaccine allergy

KW - vaccine desensitization

KW - vaccine hesitancy

UR - http://www.scopus.com/inward/record.url?scp=85144705403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144705403&partnerID=8YFLogxK

U2 - 10.1016/j.jacig.2022.04.005

DO - 10.1016/j.jacig.2022.04.005

M3 - Article

AN - SCOPUS:85144705403

SN - 2772-8293

VL - 1

SP - 175

EP - 177

JO - Journal of Allergy and Clinical Immunology: Global

JF - Journal of Allergy and Clinical Immunology: Global

IS - 3

ER -

Safety and efficacy of graded dosing of Pfizer-BioNTech mRNA COVID-19 vaccine after an immediate hypersensitivity reaction to first dose

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this